TERT promoter mutations and telomerase reactivation in urothelial cancer | Zendy

Sumit Borah | Zendy; Linghe Xi | Zendy; Arthur J. Zaug | Zendy; Natasha M. Powell | Zendy; Garrett M. Dancik | Zendy; Scott B. Cohen | Zendy; James C. Costello | Zendy; Dan Theodorescu | Zendy; Thomas R. Cech | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

TERT promoter mutations and telomerase reactivation in urothelial cancer

Author(s) -

Sumit Borah,

Linghe Xi,

Arthur J. Zaug,

Natasha M. Powell,

Garrett M. Dancik,

Scott B. Cohen,

James C. Costello,

Dan Theodorescu,

Thomas R. Cech

Publication year - 2015

Publication title -

science

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 12.556

H-Index - 1186

eISSN - 1095-9203

pISSN - 0036-8075

DOI - 10.1126/science.1260200

Subject(s) - telomerase , telomere , telomerase reverse transcriptase , biology , cancer research , microbiology and biotechnology , gene , protein subunit , mutation , cancer , urothelial cancer , telomerase rna component , bladder cancer , genetics

The downstream effects of false promotion Special DNA sequences at the ends of chromosomes, called telomeres, are replenished by a dedicated enzyme called telomerase. A subset of human tumors harbors mutations in the promoter region of the TERT gene, which codes for a subunit of telomerase. Borahet al. explored the downstream effects of TERT promoter mutations in cells derived from urothelial (urinary tract) cancers. The mutations were associated with aberrantly high levels of TERT mRNA, TERT protein and telomerase activity, and longer telomeres. A small study of clinical samples suggested that high levels of TERT mRNA may be a marker of more aggressive urothelial cancers.Science , this issue p.1006

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research